G1 Therapeutics Inc (GTHX)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:G1 Therapeutics Inc (GTHX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014228
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:33
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
G1 Therapeutics Inc (G1 Therapeutics), formerly G Zero Therapeutics Inc is a healthcare company that develops novel, and small molecule therapies. The company pipeline products include CDK4/6, trilaciclib G1T28 a drug candidate; G1T38 a potential best compound, and G1T48. It undertakes discovery and development of innovative small molecules for utilization in cancer therapy and biodefense applications. G1 Therapeutics discovers new small molecule-based methods that prevent the hematological side effects of cancer chemotherapy and exposure to ionizing radiation. The company also develops small molecules to target specific proteins associated with cell proliferation and growth. It operates through its laboratory located Research Triangle Park. G1 Therapeutics is headquartered in Research Triangle Park, North Carolina, the US.

G1 Therapeutics Inc (GTHX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
G1 Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
G1 Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
G1 Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
G1 Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
G1 Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
G1 Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
G1 Therapeutics Raises USD47 Million in Series C Financing 11
G1 Therapeutics Raises USD33 Million in Series B Financing 13
G1 Therapeutics Raises US$12.5 Million In Series A Financing 15
G-Zero Therapeutics Raises US$1.3 Million In Venture Financing 16
G1 Therapeutics Raises US$0.6 Million In Seed Financing 17
G1 Therapeutics Raises US$0.8 Million In Venture Financing 18
Partnerships 19
G1 Therapeutics Enters into Agreement with Genentech 19
Licensing Agreements 20
G1 Therapeutics Amends Licensing Agreement with Board of Trustees of the University of Illinois 20
Equity Offering 21
G1 Therapeutics Raises USD116.7 Million in IPO 21
G1 Therapeutics Inc – Key Competitors 23
G1 Therapeutics Inc – Key Employees 24
G1 Therapeutics Inc – Locations And Subsidiaries 25
Head Office 25
Recent Developments 26
Financial Announcements 26
Nov 08, 2017: G1 Therapeutics Reports Third Quarter 2017 Financial Results and Recent Operational Highlights 26
Aug 09, 2017: G1 Therapeutics Reports Second Quarter 2017 Financial Results and Recent Operational Highlights 27
Corporate Communications 29
Jul 13, 2017: G1 Therapeutics Appoints Sir Andrew Witty to Board of Directors 29
Product News 30
04/15/2016: G1 Therapeutics to Present Preliminary clinical data on CDK4/6 Inhibitor G1T28 at the 2016 American Association for Cancer Research Annual Meeting 30
Clinical Trials 31
Jan 10, 2017: G1 Therapeutics Initiates Phase 2 trial of Trilaciclib in Triple-Negative Breast Cancer 31
Nov 21, 2016: G1 Therapeutics to Present Positive Clinical and Preclinical Data on CDK4/6 Inhibitor G1T28 at December Scientific Conferences 32
Appendix 33
Methodology 33
About GlobalData 33
Contact Us 33
Disclaimer 33

List of Tables
G1 Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
G1 Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
G1 Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
G1 Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
G1 Therapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017 8
G1 Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
G1 Therapeutics Raises USD47 Million in Series C Financing 11
G1 Therapeutics Raises USD33 Million in Series B Financing 13
G1 Therapeutics Raises US$12.5 Million In Series A Financing 15
G-Zero Therapeutics Raises US$1.3 Million In Venture Financing 16
G1 Therapeutics Raises US$0.6 Million In Seed Financing 17
G1 Therapeutics Raises US$0.8 Million In Venture Financing 18
G1 Therapeutics Enters into Agreement with Genentech 19
G1 Therapeutics Amends Licensing Agreement with Board of Trustees of the University of Illinois 20
G1 Therapeutics Raises USD116.7 Million in IPO 21
G1 Therapeutics Inc, Key Competitors 23
G1 Therapeutics Inc, Key Employees 24

★海外企業調査レポート[G1 Therapeutics Inc (GTHX)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Gartner Inc (IT):企業の財務・戦略的SWOT分析
    Gartner Inc (IT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Biolase Inc (BIOL):企業の財務・戦略的SWOT分析
    Biolase Inc (BIOL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Diagnostica Stago Inc:企業の製品パイプライン分析2018
    Summary Diagnostica Stago Inc (Stago), a subsidiary of Diagnostica Stago SAS, is a medical device company that develops and distributes in-vitro diagnostic products. The company develops coagulation automation systems. It provides products such as hemostasis analyzers, viscosity based detection syst …
  • Fresenius Kabi USA LLC:企業の戦略的SWOT分析
    Fresenius Kabi USA LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Seplat Petroleum Development Company Plc (SEPLAT):石油・ガス:M&Aディール及び事業提携情報
    Summary Seplat Petroleum Development Company Plc (Seplat) is an independent upstream exploration and production company that offers development and operation of oil and natural gas reserves and production assets. The company produces oil from fileds such as Amukpe, Oben, Okporhuru, Ovhor, Orogho, Sa …
  • Sartorius AG (SRT)-医療機器分野:企業M&A・提携分析
    Summary Sartorius AG (Sartorius) manufactures and distributes laboratory and process technology equipment. The company’s lab products portfolio includes laboratory instruments, such as pipettes, laboratory water purification systems, weight sets and lab balances. It provides bioprocess solutions for …
  • Rexnord Corp (RXN):電力:M&Aディール及び事業提携情報
    Summary Rexnord Corp (Rexnord) offers process and motion control, and water management products. The company designs, manufactures, markets and services mechanical components, and water flow control and conservation products. Its product portfolio includes motion control products, aerospace componen …
  • Multi-Color Corp (LABL):企業の財務・戦略的SWOT分析
    Summary Multi-Color Corp (Multi-Color) is a paper and packaging company that develops, manufactures and markets packaging labels. The company offers products such as self adhesive, RFID and NFC, decals and overlays, luminescent, membrane switches, nameplates and signage, foams and gaskets, domed lab …
  • Panhandle Oil and Gas Inc (PHX):企業の財務・戦略的SWOT分析
    Panhandle Oil and Gas Inc (PHX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Daicel Corp (4202):企業の財務・戦略的SWOT分析
    Daicel Corp (4202) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • BRF SA:企業の戦略・SWOT・財務分析
    BRF SA - Strategy, SWOT and Corporate Finance Report Summary BRF SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, prov …
  • Lincoln Electric Cooperative Inc:企業の戦略的SWOT分析
    Lincoln Electric Cooperative Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pr …
  • MRF Limited:企業の戦略・SWOT・財務情報
    MRF Limited - Strategy, SWOT and Corporate Finance Report Summary MRF Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Terumo BCT Inc:企業の戦略的SWOT分析
    Terumo BCT Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Oryzon Genomics SA (ORY):企業の財務・戦略的SWOT分析
    Summary Oryzon Genomics SA (Oryzon) is a clinical stage biopharmaceutical company that offers discovers and develops epigenetic therapies to treat oncology and neurodegenerative diseases. The company offers epigenetics, a regulatory system that controls gene expression without affecting the makeup o …
  • Adamis Pharmaceuticals Corp (ADMP):企業の財務・戦略的SWOT分析
    Summary Adamis Pharmaceuticals Corp (Adamis), formerly Cellegy Pharmaceuticals Inc, is a biopharmaceutical company that develops therapies in areas of respiratory disease and allergy. The company offers pipeline product, epinephrine pre-filled syringe is developed for anaphylactic reactions such as …
  • CG Power and Industrial Solutions Ltd (CGPOWER):企業の財務・戦略的SWOT分析
    CG Power and Industrial Solutions Ltd (CGPOWER) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key st …
  • Sammons Enterprises Inc:企業の戦略・SWOT・財務情報
    Sammons Enterprises Inc - Strategy, SWOT and Corporate Finance Report Summary Sammons Enterprises Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • United Insurance Holdings Corp.:企業の戦略・SWOT・財務情報
    United Insurance Holdings Corp. - Strategy, SWOT and Corporate Finance Report Summary United Insurance Holdings Corp. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Mediware Information Systems Inc-製薬・医療分野:企業M&A・提携分析
    Summary Mediware Information Systems Inc (Mediware) is a healthcare solutions company that designs, develops and commercializes specialized healthcare software. It provides software to healthcare and human service providers and payers. The company’s portfolio of solutions are equipped in blood banks …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆